Skip to content
PIL Logo

Forxiga 5 mg & 10 mg film coated tablets

Last Updated on eMC 26-Apr-2017 View document  | AstraZeneca UK Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 26-Apr-2017 and displayed until Current

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 01-Feb-2017 and displayed until 26-Apr-2017

Reasons for adding or updating:

  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision

Updated on 16-May-2016 and displayed until 01-Feb-2017

Reasons for adding or updating:

  • Change to section 6 - date of revision
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects

Updated on 07-Jan-2015 and displayed until 16-May-2016

Reasons for adding or updating:

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 14-Oct-2014 and displayed until 07-Jan-2015

Reasons for adding or updating:

  • Change to section 6 - marketing authorisation holder

Updated on 07-Aug-2014 and displayed until 14-Oct-2014

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 20-Dec-2013 and displayed until 07-Aug-2014

Reasons for adding or updating:

  • Change to section 3 - how to take/use
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 04-Nov-2013 and displayed until 20-Dec-2013

Reasons for adding or updating:

  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 02-Oct-2013 and displayed until 04-Nov-2013

Reasons for adding or updating:

  • Change to section 6 - date of revision
  • Correction of spelling/typing errors

Updated on 19-Aug-2013 and displayed until 02-Oct-2013

Reasons for adding or updating:

  • Correction of spelling/typing errors

Updated on 19-Nov-2012 and displayed until 19-Aug-2013

Reasons for adding or updating:

  • New PIL for new product

Company contact details

AstraZeneca UK Limited

Company image
Address

Horizon Place, 600 Capability Green, Luton, Bedfordshire, LU1 3LU

Fax

+44 (0)1582 838 000

Medical Information e-mail
Medical Information Fax

+44 (0)1582 838 003

Telephone

+44 (0)1582 836 000

Medical Information Direct Line

0800 783 0033

Customer Care direct line

+44 (0)1582 837 837

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

dapagliflozin propanediol monohydrate

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue